Introduction Cancer faces a number of physiological challenges, including vascular endothelial pores, uneven blood supply, and heterogeneous architecture (Jain, 1989; Jain, 2001). It is critical to overcome these barriers for a drug to be effective. For medication delivery, cancer represents a massive biological problem (Baker and Choi, 2005). The mode of distribution has a big impact on cancer therapy. Patients with cancer employed a variety of anticancer medications in the past, but these treatments were proven to be ineffective and to have significant adverse effects. Nanoparticles have attracted scientists' interest owing to their multifunctional properties. The use of tailored drug delivery nanoparticles to treat cancer is the most recent medical breakthrough. Nanomaterials are at the forefront of nanotechnology's constantly evolving field. Nanoparticles' applicability in cancer medication delivery are limitless, with new ones being developed all the time. This evaluation is based on the positive implications of these platforms for cancer diagnostics and treatments innovation. Nanoparticles are appealing for cancer therapy for a variety of reasons: they have unique pharmacokinetics, including minimal renal filtration; they have high surface-to-volume ratios, allowing modification with a variety of surface functional groups that home, internalise or stabilise; and they can be made from a variety of materials to enclose or solubilize therapeutic agents for drug delivery or to provide exclusive optical, magnetic, and elastomeric properties. The structure of a nanoparticle core, coating, and surface functional groups lends itself to modular design, allowing features and functional moieties to be swapped out or mixed. Although much of the functionality of nanoparticles has been established, including some clinically approved drug formulations and imaging agents (Harisinghani and Weissleder, 2004; Gordon et al., 2001), the merging of these into nanocarriers (nanoparticles) capable of targeting, imaging, and delivering therapeutics is an exciting area of research with great potential for cancer treatment in the A systematic review on nanoparticles: A ubiquitous approach for anti-tumour drug delivery and cancer management Aman Shukla, Manju Prajapati, Vishal Shrivastava* School of Pharmacy, LNCT University, JK Town, Sarvardham, C-Sector, Kolar Road, Bhopal, 462042, Madhya Pradesh, India * Corresponding Author: Address for Vishal Shrivastava School of Pharmacy, LNCT University, JK Town, Sarvardham, C- Sector, Kolar Road, Bhopal, 462042, Madhya Pradesh, India Email: shrivastav.vishal16@gmail.com Abstract The goal of this study was to examine current research on nanotechnology-based medication delivery. Pharmaceutical nanocarriers currently in use, such as microspheres, dendrimers, nanoparticles, micelles, polymeric nanoparticles, and others, have a wide range of useful properties, including longevity in the blood, which allows for accumulation in pathological areas with reduced vasculature; specific targeting to specific disease sites; improved intracellular penetration of nonmaterial with contrast properties, which allows for direct visualisation. Some pharmacological carriers have already entered clinical trials, while others are still in the early stages of research. Furthermore, the development of multifunctional nanocarriers with desirable qualities might greatly improve the efficacy of a variety of therapeutic and diagnostic techniques. These cutting-edge materials function at the nanoscale level and provide new and powerful imaging, diagnostic, and treatment techniques. Data from research papers published in journals, data from different publications, and other internet accessible material were used to compile various reports. A list of several medication delivery methods through NP is offered, along with its benefits and drawbacks. Nanotechnology is a breakthrough invention that has a broad range of applications in disciplines such as medicine, communications, diagnostics, and electronics. Keywords: Nanotechnology, multifunctional nanocarriers, cancer, drug delivery, imaging agents Review Article Received: 12 October 2021 Revised: 18 November 2021 Accepted: 3 December 2021 www.apjonline.in DOI: https://doi.org/10.31024/apj.2021.6.6.3 2456-1436/Copyright © 2021, N.S. Memorial Scientific Research and Education Society. This is an open access article under the CC BY- NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Advance Pharmaceutical Journal 2021; 6(6):157-168 157